Application Guide Ion Exchange Resins for Pharmaceutical Production D em ineralisation of W ater
Many pharmaceutical processes require softened, or demineralized, water in theirmanufacturing process. Purolite produces the whole range of cation and anionexchange resins required to soften, or totally demineralize, water. These resins areproduced to meet FDA and EU regulatory requirements, which specify permittedchemicals used in their manufacture, maximum release of TOC and other chemicalsto the product water, together with analytical methods for their detection and theconditions of use of the resin products.
manufacture is often treated by UV radiation, immediately following ion exchange orat the point of use. D rug Purification
Ion exchange resins and adsorbents can be used in many different drug-processingapplications,
stabilisation . Purification alone, for example, may consist of different stages andprocesses: chromatographic separation; decolo rization; deashing; metals removal; andconversion. The process may also take advantage of heterogene ous catalyticreactions
The use ion exchange resins and selective adsorbents results in the advantage ofhigher purity of the final product, together with minimization of losses, due the highcapacity and selectivity of the resins.
The most suitable ion exchange resins and adsorbents for a given application areselected on consideration of functional groups (weak or strong, acid or base, neutral),porosity, pore diamete r, hydrophilic / hydrophobic nature, and ability to resist fouling. Often, the final resin selection is a compromise between the capacity, selectivity andelution profile. Industrial antibiotics production from fermentation broths is a significantarea of both ion exchange and synthetic adsorbent use. USA Europe Asia Pacific Telephone: (1) 610-668-9090
Telephone: +44 1443 229334 Telephone: +86 571 876 31385
Fax: (1) 610-668-8139 Fax: +44 1443 227073
www.purolite.com C ephalosporin-C
The manufacture of Cephalosporin -C typically takes place in a number of sequentialsteps.
A fermentation broth is produced containing 5 to 15 g/l cephalosporin, together withimpurities, which is then passed through a weak base anion exchanger to removeresidual ion s and to decolorize . Decolonization is completed using an adsorbent resin,prior
Cephalosporin -C is eluted from the adsorbent resin using isopropyl alcohol, andconverted to the sodium form using a strong acid cation resin. Purolite manufactures allresins and adsorbents for these processes
Streptom ycin Sulphate Production
The manufacture of Streptomycin is typically carried out in the following sequential steps. A fermentation broth is produced containing Streptomycin in the presence ofimpurities. The fermentation broth is filtered, and the clear extract passed through a weakacid cation bed to extract the Streptomycin. The Streptomycin is eluted using hydrochloricacid, decolo rized and converted to the sulphate form using a strong base anionresin. Freezing and drying achieve purification . O ther Processes and Applications
The extraction of opium alkaloids, enzymes (such as, lysozyme from albumen),heparin, together with the extraction
decolo rization and stabilization of vitamins, are further examples of the applicationof
Sodium form strong acid cation exchangers are used to remove calcium ions fromcollected blood to inhibit coagulation without the use of additional chemicals. Carboxylic resins are used to remove zinc ions from blood plasma. Strong
are also used in the analytical determination
sodium levels in blood, and in the analysis of urine. Purolite offers hydrophobic adsorbent products for adsorption and reverse phase chromatography to separate proteins, insuline, peptides, nucleonic acids, targeted antibiotics and many more specific pharmaceutica l compounds and solutions. USA Europe Asia Pacific Telephone: (1) 610-668-9090
Telephone: +44 1443 229334 Telephone: +86 571 876 31385
Fax: (1) 610-668-8139 Fax: +44 1443 227073
www.purolite.com
HEMOPET/HEMOLIFE 11330 Markon Drive, Garden Grove, California 92841 TREATMENT OF BLEEDING DISORDERS VON WILLEBRAND’S DISEASE (VWD) For short-term control of bleeding or prophylaxis for dogs at risk to bleed from vWD (vonWillebrands disease):1. For elective procedures, assess bleeding potential first with a toenail or mucosal bleeding time. Normal2. Use L-thyroxine therapy at 0.1 m
Privacy and Security policy We at ScratchMania.com hold your privacy and security in the highest regard. ScratchMania.com is committed to respect and protect your privacy. Account Information: Your information is important to us. All the Account Information that you supply during the account creation process is kept strictly confidential. When your information passes from your computer t
Application Guide
C ephalosporin-C